Analyses of mutations selected by passaging a chimeric flavivirus identify mutations that alter infectivity and reveal an interaction between the structural proteins and the nonstructural glycoprotein NS1

Virology

Volumn 421, Issue 2, 2011, Pages 96-104

  Winkelmann, Evandro R ^a   Widman, Douglas G ^a,b   Suzuki, Ryosuke ^a,c   Mason, Peter W ^a,d  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Chimera; Flavivirus; Packaging; RepliVAX; Single cycle virus

Indexed keywords

E PROTEIN; M PROTEIN; MUTANT PROTEIN; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 2A; NONSTRUCTURAL PROTEIN 3; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CHIMERA; CONTROLLED STUDY; DENGUE VIRUS 2; E GENE; FLAVIVIRUS; GENE CASSETTE; GENE MUTATION; M GENE; MOLECULAR WEIGHT; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REPLICON; RIBOSOMAL FRAMESHIFTING; RNA SEQUENCE; SEQUENCE ALIGNMENT; VIRION; VIRUS ENVELOPE; VIRUS GENE; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS REPLICATION;

ANIMALS; CELL LINE; CRICETINAE; DENGUE VIRUS; FRAMESHIFTING, RIBOSOMAL; MUTATION; RNA HELICASES; SERINE ENDOPEPTIDASES; VIRAL NONSTRUCTURAL PROTEINS; VIRAL STRUCTURAL PROTEINS; VIRUS ASSEMBLY;

DENGUE VIRUS; FLAVIVIRUS; MIRIDAE; WEST NILE VIRUS;

EID: 80355146859     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.09.007     Document Type: Article

References (37)

1. Alcon S., Talarmin A., Debruyne M., Falconar A., Deubel V., Flamand M. Enzyme-linked immunosorbent assay specific to Dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J. Clin. Microbiol. 2002, 40(2):376-381.
2. Anez G., Men R., Eckels K.H., Lai C.J. Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in rhesus macaques. J. Virol. 2009, 83(20):10384-10394.
3. Bourne N., Scholle F., Silva M.C., Rossi S.L., Dewsbury N., Judy B., De Aguiar J.B., Leon M.A., Estes D.M., Fayzulin R., Mason P.W. Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production. J. Virol. 2007, 81(17):9100-9108.
4. Fan W.F., Mason P.W. Membrane association and secretion of the Japanese encephalitis virus NS1 protein from cells expressing NS1 cDNA. Virology 1990, 177(2):470-476.
5. Fayzulin R., Scholle F., Petrakova O., Frolov I., Mason P.W. Evaluation of replicative capacity and genetic stability of West Nile virus replicons using highly efficient packaging cell lines. Virology 2006, 351(1):196-209.
6. Firth A.E., Atkins J.F. A conserved predicted pseudoknot in the NS2A-encoding sequence of West Nile and Japanese encephalitis flaviviruses suggests NS1' may derive from ribosomal frameshifting. Virol. J. 2009, 6:14.
7. Fonseca B.A.L. Vaccinia-vectored dengue vaccine candidates elicit neutralizing antibodies in mice. Doctoral thesis 1994, Yale University, New Haven, CT.
8. Gilfoy F., Fayzulin R., Mason P.W. West Nile virus genome amplification requires the functional activities of the proteasome. Virology 2009, 385(1):74-84.
9. Halstead S.B., Thomas S.J. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev. Vaccines 2011, 10(3):355-364.
10. Higuchi R., Krummel B., Saiki R.K. A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res. 1988, 16(15):7351-7367.
11. Ishikawa T., Widman D.G., Bourne N., Konishi E., Mason P.W. Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis. Vaccine 2008, 26(22):2772-2781.
12. Junjhon J., Edwards T.J., Utaipat U., Bowman V.D., Holdaway H.A., Zhang W., Keelapang P., Puttikhunt C., Perera R., Chipman P.R., Kasinrerk W., Malasit P., Kuhn R.J., Sittisombut N. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J. Virol. 2010, 84(16):8353-8358.
13. Kitai Y., Shoda M., Kondo T., Konishi E. Epitope-blocking enzyme-linked immunosorbent assay to differentiate West Nile virus from Japanese encephalitis virus infections in equine sera. Clin. Vaccine Immunol. 2007, 14(8):1024-1031.
14. Konishi E., Pincus S., Fonseca B.A., Shope R.E., Paoletti E., Mason P.W. Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology 1991, 185(1):401-410.
15. Kroschewski H., Allison S.L., Heinz F.X., Mandl C.W. Role of heparan sulfate for attachment and entry of tick-borne encephalitis virus. Virology 2003, 308(1):92-100.
16. Lee E., Lobigs M. Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry. J. Virol. 2000, 74(19):8867-8875.
17. Lee E., Lobigs M. Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. J. Virol. 2002, 76(10):4901-4911.
18. Lee E., Hall R.A., Lobigs M. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J. Virol. 2004, 78(15):8271-8280.
19. Lee E., Wright P.J., Davidson A., Lobigs M. Virulence attenuation of Dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. J. Gen. Virol. 2006, 87(Pt 10):2791-2801.
20. Li L., Lok S.M., Yu I.M., Zhang Y., Kuhn R.J., Chen J., Rossmann M.G. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 2008, 319(5871):1830-1834.
21. Libraty D.H., Young P.R., Pickering D., Endy T.P., Kalayanarooj S., Green S., Vaughn D.W., Nisalak A., Ennis F.A., Rothman A.L. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J. Infect. Dis. 2002, 186(8):1165-1168.
22. Lindenbach B.D., Rice C.M. Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function. J. Virol. 1999, 73(6):4611-4621.
23. Lindenbach B.D., Theil H.-J., Rice C.M. Flaviviridae: the viruses and their replication. Fields Virology 2007, Vol. 1:1101-1152. Lippincott Williams & Wilkins, Philadelphia, 2 vols. Fifth ed. D.M. Knipe, P.M. Howley (Eds.).
24. Mandl C.W., Allison S.L., Holzmann H., Meixner T., Heinz F.X. Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site. J. Virol. 2000, 74(20):9601-9609.
25. Mason P.W. Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells. Virology 1989, 169(2):354-364.
26. Mason P.W., Shustov A.V., Frolov I. Production and characterization of vaccines based on flaviviruses defective in replication. Virology 2006, 351(2):432-443.
27. Melian E.B., Hinzman E., Nagasaki T., Firth A.E., Wills N.M., Nouwens A.S., Blitvich B.J., Leung J., Funk A., Atkins J.F., Hall R., Khromykh A.A. NS1' of flaviviruses in the Japanese encephalitis virus serogroup is a product of ribosomal frameshifting and plays a role in viral neuroinvasiveness. J. Virol. 2010, 84(3):1641-1647.
28. Muylaert I.R., Chambers T.J., Galler R., Rice C.M. Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence. Virology 1996, 222(1):159-168.
29. Muylaert I.R., Galler R., Rice C.M. Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation. J. Virol. 1997, 71(1):291-298.
30. Patkar C.G., Kuhn R.J. Yellow Fever virus NS3 plays an essential role in virus assembly independent of its known enzymatic functions. J. Virol. 2008, 82(7):3342-3352.
31. Staples J.E., Gershman M., Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2010, 59(RR-7):1-27.
32. Suzuki R., Winkelmann E.R., Mason P.W. Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2. J. Virol. 2009, 83(4):1870-1880.
33. Thompson J.F., Hayes L.S., Lloyd D.B. Modulation of firefly luciferase stability and impact on studies of gene regulation. Gene 1991, 103(2):171-177.
34. van der Schaar H.M., Rust M.J., Waarts B.L., van der Ende-Metselaar H., Kuhn R.J., Wilschut J., Zhuang X., Smit J.M. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J. Virol. 2007, 81(21):12019-12028.
35. Widman D.G., Ishikawa T., Fayzulin R., Bourne N., Mason P.W. Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. Vaccine 2008, 26(22):2762-2771.
36. Youn S., Cho H., Fremont D.H., Diamond M.S. A short N-terminal peptide motif on flavivirus nonstructural protein NS1 modulates cellular targeting and immune recognition. J. Virol. 2010, 84(18):9516-9532.
37. Yu I.M., Zhang W., Holdaway H.A., Li L., Kostyuchenko V.A., Chipman P.R., Kuhn R.J., Rossmann M.G., Chen J. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 2008, 319(5871):1834-1837.